Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Tuesday morning. The brokerage issued a sell rating on the stock.

Bio-Path Stock Up 0.1%

BPTH stock opened at $0.18 on Tuesday. The company has a fifty day moving average price of $0.16 and a 200-day moving average price of $0.55. Bio-Path has a 52-week low of $0.12 and a 52-week high of $4.55.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.